1st Patient Treated in Phase 3 Trial of RDEB Gene Therapy, D-Fi

A first patient has been treated in a Phase 3 trial testing the investigational gene therapy D-Fi (debcoemagene autoficel), formerly known as FCX-007, on wounds in people with recessive dystrophic epidermolysis bullosa (RDEB). “Our late-stage Phase 3 trial of D-Fi continues to progress for the localized treatment…

$75M Funding to Advance Gene Therapy for RDEB Entering Phase 3 Trial

Castle Creek Biosciences has received a $75 million investment to advance its gene therapy program, including FCX-007, a treatment candidate for people with recessive dystrophic epidermolysis bullosa (RDEB) that now in a pivotal clinical trial. “We are proud to have the strategic support of world-class investors whose impact…